🇰🇷 Arcapta Neohaler in South Korea

Arcapta Neohaler (INDACATEROL) regulatory status in South Korea.

Marketing authorisation

MFDS

  • Status: likely_approved

Arcapta Neohaler in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Respiratory approved in South Korea

Frequently asked questions

Is Arcapta Neohaler approved in South Korea?

Yes. MFDS has authorised it.

Who is the marketing authorisation holder for Arcapta Neohaler in South Korea?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.